Pembrolizumab and Cabozantinib in patients with Recurrent Metastatic Head and Neck Squamous Cell Carcinoma

We conducted a phase II multicenter single arm trial of pembrolizumab and cabozantininb in patients with Recurrent Metastatic Head and Neck Squamous Cell Carcinoma). We extracted DNA from 16 tumors and 4 germline DNA as a control and performed whole genome sequencing to determine tumor mutation burden (TMB). The TMB was associated with response data.